步长制药：关于控股子公司拟对外投资设立子公司的进展公告

Core Viewpoint - The company announced a strategic investment to establish a new subsidiary, aiming to enhance its operational development and expand its market presence in the pharmaceutical sector [2]. Group 1: Investment Details - The company plans to invest in a new company named Shaanxi Buchang Yishuyue Co., Ltd., with a registered capital of 5 million yuan [2]. - The company will contribute 4 million yuan, holding an 80% stake, while Zero Medical Technology (Shaanxi) will invest 1 million yuan for a 20% stake [2]. - Following the completion of this investment, Shaanxi Buchang Yishuyue will be included in the company's consolidated financial statements [2]. Group 2: Corporate Governance - The fifth session of the company's board of directors will convene on June 20, 2025, to review and approve the investment proposal [2]. - The establishment of the new subsidiary is part of the company's overall development plan [2]. Group 3: Regulatory Compliance - The new company has completed its business registration and obtained a business license from the Xi'an Market Supervision Administration [2].